Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,463 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05189028 | Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer | unknown | Phase 3 | 290 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT05446324 | Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer(SENGA) | unknown | Phase 3 | 10 | UMC UtrechtOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval(MITO-8) | unknown | Phase 3 | 215 | National Cancer Institute, NaplesOTHER | 3 | Nov 13, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT04596800 | Prehabilitation Plus ERAS Versus ERAS in Gynecologic Oncology: a Randomized Clinical Trial(PROPER) | unknown | Phase 3 | 194 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00411138 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer(PORTEC-3) | unknown | Phase 3 | 670 | Leiden UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04311073 | Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies | unknown | Phase 3 | 50 | Eastern Virginia Medical SchoolOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04792749 | Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer | unknown | Phase 3 | 77 | Samsung Medical CenterOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer(MITO-7) | unknown | Phase 3 | 800 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT05620355 | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | unknown | Phase 3 | 312 | Bio Genuine (Shanghai) Biotech Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03278717 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients(ICON9) | unknown | Phase 3 | 330 | University College, LondonOTHER | 4 | Sep 27, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT05467319 | Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS(FORGE) | unknown | Phase 3 | 82 | Alberta Health Services, CalgaryOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT05371301 | Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer | unknown | Phase 3 | 200 | Fudan UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | unknown | Phase 3 | 813 | Gynecologic Oncology GroupNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment(NItCHE-MITO33) | unknown | Phase 3 | 427 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT01611766 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | unknown | Phase 3 | 356 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03709316 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | unknown | Phase 3 | 384 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04337632 | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer | unknown | Phase 3 | 338 | Hunan Cancer HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04646954 | DNA Methylation Testing for the Screening of Uterine Cervical Lesion | unknown | Phase 3 | 12,000 | Lei LiOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04473339 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | unknown | Phase 3 | 280 | CAI HongbingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03371693 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer(HIPECOV) | unknown | Phase 3 | 112 | Zhongnan HospitalOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02879513 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | unknown | Phase 3 | 290 | RenJi HospitalOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT03693248 | Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer(ROCOCO) | unknown | Phase 3 | 298 | Seoul National University HospitalOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03373058 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery(EHTASEOCCS) | unknown | Phase 3 | 310 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03220932 | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer(HIPOVA-01) | unknown | Phase 3 | 132 | Hospices Civils de LyonOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 280 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04101760 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | unknown | Phase 3 | 200 | Lei LiOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT00193739 | Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix(NACTcervix) | unknown | Phase 3 | 635 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)(EPITOC) | unknown | Phase 2 / Phase 3 | 164 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00806117 | Comparison of Different Subsequent Treatments After Radical Surgery(STARS) | unknown | Phase 3 | 1,080 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00807768 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | unknown | Phase 3 | 601 | Gynecologic Oncology GroupNETWORK | 2 | Mar 20, 2019 | clinicaltrials |
| NCT01561586 | Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer(TACO) | unknown | Phase 3 | 374 | Korea Cancer Center HospitalOTHER | 4 | Feb 27, 2019 | clinicaltrials |
| NCT03740464 | Long-acting G-CSF for Febrile Neutropenia | unknown | Phase 3 | 556 | Lei LiOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT02942537 | Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment(MYOMIC1) | unknown | Phase 2 / Phase 3 | 36 | Karolinska InstitutetOTHER | 1 | Oct 2, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Apr 17, 2024source: clinicaltrials